AACR conference examines how societal framework of racism drives cancer disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The global coronavirus pandemic has torn the veil that dimmed the nation’s awareness of the breadth and depth of health disparities, including cancer health disparities.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Steven R. Patierno, PhD
Deputy director, Duke Cancer Institute; Professor of medicine, pharmacology and cancer biology, professor of family medicine and community health, Duke University School Medicine; Conference co-chair, AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
Steven R. Patierno, PhD
Deputy director, Duke Cancer Institute; Professor of medicine, pharmacology and cancer biology, professor of family medicine and community health, Duke University School Medicine; Conference co-chair, AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login